|
News for: |
|
You will land on a page at the National Library of Medicine where you can drill down to consumer info, research citations, product labelling, toxicology and more. FindingHealthOnline is the world's leading health-pharma search portal and decision engine. It helps you drill down to very detailed information without interference from commercial sites that now dominate Bing, Google, and Yahoo. Near the top of our pages, you will find a link to content that best matches your query.
|
|
|
FDA Approval Activities for this Drug…
Xopenex (levalbuterol HCl) Inhalation Solution, Sepracor NDA 20-837/S10 7/18/03 7/28/03 Xopenex (levalbuterol HCl) Inhalation Solution, 0.31 mg/3 mL, 0.63 mg/3 mL & 1.25 mg/3 mL Unit-Dose Vials Sepracor Inc Sepracor NDA 20-837/S6 1/30/02 2/8/02 Xopenex Indications: For the treatment or prevention of bronchospasm in children 6 years of age and older with reversible obstructive airway disease. Xopenex (levalbuterol HCl) Inhalation Solution, 0.63 mg/3 mL & 1.25 mg/3 mL Unit-Dose Vials Sepracor NDA 20-837 3/25/99 3/29/99 3/29/99 6/20/01 Xopenex Indications: For the treatment or prevention of bronchospasm in adults and adolescents 12 years of age and older with reversible obstructive airway disease. | Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Sepracor, Approval | Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Sepracor, Labeling Revision | Xopenex (levalbuterol HCL) Inhalation Solution and Xopenex (levalbuterol HCL) Inhalation Solution Concentrate, Sepracor Inc., Labeling Revision | Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Sepracor Inc., Labeling Revision
|